Luca Bartolini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Luca Bartolini has a total of 184 co-authors. Here are the top co-authors by number of shared publications:
William D. Gaillard
Center for Neuroscience, Children's National Medical Center/The George Washington University, Washington DC, United States
8 shared publicationsSteven Jacobson
Division of Neuroimmunology and Neurovirology, NINDS, NIH, Bethesda, MD, United States
6 shared publicationsAdrian Bumbut
Center for Neuroscience, Children's National Medical Center/The George Washington University, Washington DC, United States
4 shared publications- Aravind Ganesh
University of Calgary
4 shared publications James M. Chamberlain
Emergency Medicine and Trauma Services, Children's National Medical Center, Washington DC, United States
4 shared publications- Stefano Sartori
Department of Women's and Children's Health, University of Padua, Italy; Paediatric Neurology and Neurophysiology Unit, Pediatric Division, Department of Women's and Children's Health, University Hospital of Padua, Padua, Italy; Neuroimmunology Group, Paediatric Research Institute "Città della Speranza, Padua, Italy; Department of Neuroscience, University Hospital of Padua, Padua, Italy
4 shared publications
Latest Publications
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (6) , e200683
From Building Foundations to Shaping Practice
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (6) , e200683
From Building Foundations to Shaping Practice
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (3) , e200629
A Message From the Editors to Our Reviewers
- 1 June 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (3) , e200629
A Message From the Editors to Our Reviewers
- 26 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (10) , e218171
Updating Neurology ® Journals' Policies on AI Use, Reporting of Genetic Studies, and Protocols for Systematic Review
- 26 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (10) , e218171
Updating Neurology ® Journals' Policies on AI Use, Reporting of Genetic Studies, and Protocols for Systematic Review
- Open Access
- 18 February 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (2) , e70530
Real‐World Use of Cenobamate in Paediatric Drug‐Resistant Epilepsy: Long‐Term Efficacy, Safety, and Co‐Medication Adjustment
Background: We evaluated the real‐world efficacy, tolerability, treatment retention, and quality‐of‐life effects of cenobamate in paediatric drug‐resistant epilepsy. Methods: We retrospectively studied 78 paediatric patients with drug‐resistant epilepsy treated with cenobamate for ≥ 3 months at a tertiary epilepsy centre. We assessed seizure frequency, adverse effects, cognitive/behavioural outcomes, and changes in concomitant antiseizure medications. The primary efficacy endpoint was a ≥ 50% reduction in seizure frequency. We assessed safety through reported adverse events and clinical improvement using the Clinical Global Impression–Improvement (CGI‐I) scale. We used Kaplan–Meier analyses to assess responder rates and treatment retention over 18 months. Results: A ≥ 50% seizure reduction was achieved in 67.9% of patients including 6.4% who became seizure‐free. Polytherapy was simplified in 38% overall and in 56.6% of responders. Adverse events occurred in 43.6% of patients, were mostly mild, and led to discontinuation in only one patient (1.3%). CGI‐I indicated clinical improvement in 24.4%. Kaplan–Meier analysis showed sustained response in 93% of initial responders at 18 months. Treatment retention remained high: 94.7% at 3 months, 89.6% at 12 months, and 86.8% at 18 months. Median follow‐up was 12 months (range 3–18), with 60.3% followed for ≥ 12 months and 41% for the full 18 months. Conclusions: Our study confirms and extends recent evidence on the efficacy and favourable tolerability of cenobamate in paediatric drug‐resistant epilepsy. We observed functional improvements and polytherapy simplification, suggesting broader therapeutic benefits. These findings warrant prospective validation in specific paediatric epilepsy syndromes and may help support regulatory approval for paediatric use.
- 18 February 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (2) , e70530
Open AccessReal‐World Use of Cenobamate in Paediatric Drug‐Resistant Epilepsy: Long‐Term Efficacy, Safety, and Co‐Medication Adjustment
Background: We evaluated the real‐world efficacy, tolerability, treatment retention, and quality‐of‐life effects of cenobamate in paediatric drug‐resistant epilepsy. Methods: We retrospectively studied 78 paediatric patients with drug‐resistant epilepsy treated with cenobamate for ≥ 3 months at a tertiary epilepsy centre. We assessed seizure frequency, adverse effects, cognitive/behavioural outcomes, and changes in concomitant antiseizure medications. The primary efficacy endpoint was a ≥ 50% reduction in seizure frequency. We assessed safety through reported adverse events and clinical improvement using the Clinical Global Impression–Improvement (CGI‐I) scale. We used Kaplan–Meier analyses to assess responder rates and treatment retention over 18 months. Results: A ≥ 50% seizure reduction was achieved in 67.9% of patients including 6.4% who became seizure‐free. Polytherapy was simplified in 38% overall and in 56.6% of responders. Adverse events occurred in 43.6% of patients, were mostly mild, and led to discontinuation in only one patient (1.3%). CGI‐I indicated clinical improvement in 24.4%. Kaplan–Meier analysis showed sustained response in 93% of initial responders at 18 months. Treatment retention remained high: 94.7% at 3 months, 89.6% at 12 months, and 86.8% at 18 months. Median follow‐up was 12 months (range 3–18), with 60.3% followed for ≥ 12 months and 41% for the full 18 months. Conclusions: Our study confirms and extends recent evidence on the efficacy and favourable tolerability of cenobamate in paediatric drug‐resistant epilepsy. We observed functional improvements and polytherapy simplification, suggesting broader therapeutic benefits. These findings warrant prospective validation in specific paediatric epilepsy syndromes and may help support regulatory approval for paediatric use.
- 1 August 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (4) , e200507
Management of Patients With Mild Cognitive Impairment in the Era of Anti-Amyloid Therapy
The aim of this study was to explore practice patterns in managing mild cognitive impairment (MCI). The investigation and management of MCI is considered important because it offers the opportunity to potentially stave off conversion to dementia. However, there are few data on current practices/approaches in this area, especially worldwide; such data can help identify potential disparities and anticipate adoption of new therapies. We performed a worldwide electronic survey of neurology practitioners through the Practice Current section of Neurology® Clinical Practice with clinical and practice-related questions in November 2019-August 2021 and repeated it in May-October 2023 after the FDA's approval of aducanumab and lecanemab but before the approval of donanemab. Clinical questions addressed access to and utilization of diagnostic investigations, pharmacologic and nonpharmacologic management of MCI, and (in 2023) attitudes toward novel anti-amyloid agents. Responses were compared using the Fisher exact test and multivariable logistic regression adjusted for region, regional income, year of survey response, years in practice, and number of cognitive patients seen annually. We received 1,257 responses from 95 countries, including 237 cognitive subspecialists and 464 respondents from low-/middle-income countries. On multivariable analysis, cognitive subspecialists were more likely than other practitioners to investigate MCI with a lumbar puncture (aOR 1.90, 95% CI 1.32-2.73), luorodeoxyglucose-PET (FDG-PET) (aOR 1.45, 95% CI 1.00-2.10) and to offer pharmacotherapy if investigations suggested neurodegeneration (aOR 1.92, 95% CI 1.29-2.85). Regionally, respondents from Europe, Latin America, and Asia were more likely than those from the United States/Canada to order FDG-PET (e.g., Europe: aOR 2.38, 95% CI 1.29-4.39) and amyloid PET (Europe: aOR 3.30, 95% CI 1.85-5.87), controlling for reported access to these tests. Pharmacologic and nonpharmacologic approaches were comparable between cognitive subspecialists and other respondents. Despite concerns about safety (77.1% expressed being somewhat or very concerned), attitudes toward prescribing new anti-amyloid agents were similar among all respondents, reflecting a generally favorable attitude (e.g., 62% would prescribe anti-amyloid therapy if it was available). Our results highlight practice differences among cognitive subspecialists and other practitioners worldwide in the management of MCI. Attitudes toward anti-amyloid therapy indicate cautious optimism, with concerns about side effects but a general interest to prescribe.
- 1 August 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (4) , e200507
Management of Patients With Mild Cognitive Impairment in the Era of Anti-Amyloid Therapy
The aim of this study was to explore practice patterns in managing mild cognitive impairment (MCI). The investigation and management of MCI is considered important because it offers the opportunity to potentially stave off conversion to dementia. However, there are few data on current practices/approaches in this area, especially worldwide; such data can help identify potential disparities and anticipate adoption of new therapies. We performed a worldwide electronic survey of neurology practitioners through the Practice Current section of Neurology® Clinical Practice with clinical and practice-related questions in November 2019-August 2021 and repeated it in May-October 2023 after the FDA's approval of aducanumab and lecanemab but before the approval of donanemab. Clinical questions addressed access to and utilization of diagnostic investigations, pharmacologic and nonpharmacologic management of MCI, and (in 2023) attitudes toward novel anti-amyloid agents. Responses were compared using the Fisher exact test and multivariable logistic regression adjusted for region, regional income, year of survey response, years in practice, and number of cognitive patients seen annually. We received 1,257 responses from 95 countries, including 237 cognitive subspecialists and 464 respondents from low-/middle-income countries. On multivariable analysis, cognitive subspecialists were more likely than other practitioners to investigate MCI with a lumbar puncture (aOR 1.90, 95% CI 1.32-2.73), luorodeoxyglucose-PET (FDG-PET) (aOR 1.45, 95% CI 1.00-2.10) and to offer pharmacotherapy if investigations suggested neurodegeneration (aOR 1.92, 95% CI 1.29-2.85). Regionally, respondents from Europe, Latin America, and Asia were more likely than those from the United States/Canada to order FDG-PET (e.g., Europe: aOR 2.38, 95% CI 1.29-4.39) and amyloid PET (Europe: aOR 3.30, 95% CI 1.85-5.87), controlling for reported access to these tests. Pharmacologic and nonpharmacologic approaches were comparable between cognitive subspecialists and other respondents. Despite concerns about safety (77.1% expressed being somewhat or very concerned), attitudes toward prescribing new anti-amyloid agents were similar among all respondents, reflecting a generally favorable attitude (e.g., 62% would prescribe anti-amyloid therapy if it was available). Our results highlight practice differences among cognitive subspecialists and other practitioners worldwide in the management of MCI. Attitudes toward anti-amyloid therapy indicate cautious optimism, with concerns about side effects but a general interest to prescribe.
- 31 May 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (6) , 1-13
Congenital CMV infection and central nervous system involvement: mechanisms, treatment, and long-term outcomes
Congenital Cytomegalovirus (cCMV) infection is the leading infectious cause of non-genetic sensorineural hearing loss and a significant cause of neurodevelopmental disability in infants. This narrative review aims to describe the mechanisms by which CMV disrupts fetal brain development in early gestation, the importance of neonatal neuroimaging in predicting prognosis, and the optimal intervention for preventing neurologic sequelae. We performed a literature search on PUBMED on this topic and selected the most relevant results, including studies describing neurologic outcomes, neuroimaging, hearing loss, treatment efficacy, or follow-up recommendations in infants with cCMV, prioritizing randomized controlled trials (RCTs), systematic reviews, and expert consensus guidelines. The pathogenesis of cCMV infection is the result of various mechanisms that the virus uses to replicate in the developing fetal central nervous system; the major cause of structural damage to the brain is aberrant migration of neuronal precursors. Recent literature stresses the importance of neuroimaging and the role of neuroradiologic scores to predict neurologic sequelae. The management of infants with isolated SNHL, especially those diagnosed after the neonatal period, remains controversial, though emerging evidence suggests a potential therapeutic window up to 12 weeks of age. Follow-up protocols should be tailored based on clinical presentation, with close audiologic and developmental surveillance. Conclusions: Despite recent advances, key knowledge gaps persist regarding the mechanisms of CNS injury, optimal screening for vestibular dysfunction, neonatal biomarkers of prognosis, and treatment indications for isolated SNHL. Targeted research and standardized follow-up models are essential to improve outcomes in this vulnerable population. What is Known: • Congenital Cytomegalovirus infection is the leading infectious cause of non-genetic sensorineural hearing loss and a significant cause of neurodevelopmental disability in infants. • Neurological complications remain the most significant contributors to morbidity in cCMV infection. What is New: • Beyond classical neurological manifestations, cCMV infected babies show a high prevalence of vestibular dysfunction; neurodevelopmental sequelae are frequent, including autism, attention deficit, and learning difficulties, and may occur even in asymptomatic cases. Neuroradiologic scoring systems proved to be predictive of developmental outcomes. • This review proposes a structured follow-up model tailored to clinical and imaging findings and discusses prognostic factors that may help identify children at increased risk for late-onset sequelae.
- 31 May 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (6) , 1-13
Congenital CMV infection and central nervous system involvement: mechanisms, treatment, and long-term outcomes
Congenital Cytomegalovirus (cCMV) infection is the leading infectious cause of non-genetic sensorineural hearing loss and a significant cause of neurodevelopmental disability in infants. This narrative review aims to describe the mechanisms by which CMV disrupts fetal brain development in early gestation, the importance of neonatal neuroimaging in predicting prognosis, and the optimal intervention for preventing neurologic sequelae. We performed a literature search on PUBMED on this topic and selected the most relevant results, including studies describing neurologic outcomes, neuroimaging, hearing loss, treatment efficacy, or follow-up recommendations in infants with cCMV, prioritizing randomized controlled trials (RCTs), systematic reviews, and expert consensus guidelines. The pathogenesis of cCMV infection is the result of various mechanisms that the virus uses to replicate in the developing fetal central nervous system; the major cause of structural damage to the brain is aberrant migration of neuronal precursors. Recent literature stresses the importance of neuroimaging and the role of neuroradiologic scores to predict neurologic sequelae. The management of infants with isolated SNHL, especially those diagnosed after the neonatal period, remains controversial, though emerging evidence suggests a potential therapeutic window up to 12 weeks of age. Follow-up protocols should be tailored based on clinical presentation, with close audiologic and developmental surveillance. Conclusions: Despite recent advances, key knowledge gaps persist regarding the mechanisms of CNS injury, optimal screening for vestibular dysfunction, neonatal biomarkers of prognosis, and treatment indications for isolated SNHL. Targeted research and standardized follow-up models are essential to improve outcomes in this vulnerable population. What is Known: • Congenital Cytomegalovirus infection is the leading infectious cause of non-genetic sensorineural hearing loss and a significant cause of neurodevelopmental disability in infants. • Neurological complications remain the most significant contributors to morbidity in cCMV infection. What is New: • Beyond classical neurological manifestations, cCMV infected babies show a high prevalence of vestibular dysfunction; neurodevelopmental sequelae are frequent, including autism, attention deficit, and learning difficulties, and may occur even in asymptomatic cases. Neuroradiologic scoring systems proved to be predictive of developmental outcomes. • This review proposes a structured follow-up model tailored to clinical and imaging findings and discusses prognostic factors that may help identify children at increased risk for late-onset sequelae.
- 1 April 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (2) , e200439
2023–2024
- 1 April 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (2) , e200439
2023–2024
- 1 February 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (1) , e200376
Approach to Managing the Initial Presentation of Multiple Sclerosis
Available disease-modifying therapies (DMTs) for multiple sclerosis (MS) are rapidly expanding; although escalation approaches aim to balance safety and efficacy, emerging evidence suggests superior outcomes for people with MS who are exposed to early high-efficacy therapies. We aimed to explore practice differences in prevailing management strategies for relapsing-remitting MS. We used a worldwide electronic survey launched by the Practice Current section of Neurology® Clinical Practice. Questions pertained to a case of a 37-year-old woman presenting with optic neuritis. Respondents were asked to indicate their initial investigations, relapse management strategy, choice of disease-modifying therapy, and plan for follow-up imaging (contrast/noncontrast). Survey responses were stratified by key demographic variables along with 95% confidence intervals (95% CIs). We received 153 responses from 42 countries; 32.3% responders identified as MS specialists. There was a strong preference for intravenous delivery of high-dose corticosteroids (87.7%, 95% CI 80.7-92.5), and most of the responders (61.3%, 95% CI 52.6-69.4) indicated they would treat a nondisabling (mild sensory) MS relapse. When asked to select a single initial DMT, 56.6% (95% CI 47.6-65.1) selected a high-efficacy therapy (67.5% MS specialists vs 53.7% non-MS specialists). The most selected agents overall were fingolimod (14.7%), natalizumab (15.5%), and dimethyl fumarate (20.9%). Two-thirds of respondents indicated they would request contrast-enhanced surveillance MRI. Although there is a slight preference for initiating high-efficacy DMT at the time of initial MS diagnosis, opinions regarding the most appropriate treatment paradigm remain divided.
- 1 February 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (1) , e200376
Approach to Managing the Initial Presentation of Multiple Sclerosis
Available disease-modifying therapies (DMTs) for multiple sclerosis (MS) are rapidly expanding; although escalation approaches aim to balance safety and efficacy, emerging evidence suggests superior outcomes for people with MS who are exposed to early high-efficacy therapies. We aimed to explore practice differences in prevailing management strategies for relapsing-remitting MS. We used a worldwide electronic survey launched by the Practice Current section of Neurology® Clinical Practice. Questions pertained to a case of a 37-year-old woman presenting with optic neuritis. Respondents were asked to indicate their initial investigations, relapse management strategy, choice of disease-modifying therapy, and plan for follow-up imaging (contrast/noncontrast). Survey responses were stratified by key demographic variables along with 95% confidence intervals (95% CIs). We received 153 responses from 42 countries; 32.3% responders identified as MS specialists. There was a strong preference for intravenous delivery of high-dose corticosteroids (87.7%, 95% CI 80.7-92.5), and most of the responders (61.3%, 95% CI 52.6-69.4) indicated they would treat a nondisabling (mild sensory) MS relapse. When asked to select a single initial DMT, 56.6% (95% CI 47.6-65.1) selected a high-efficacy therapy (67.5% MS specialists vs 53.7% non-MS specialists). The most selected agents overall were fingolimod (14.7%), natalizumab (15.5%), and dimethyl fumarate (20.9%). Two-thirds of respondents indicated they would request contrast-enhanced surveillance MRI. Although there is a slight preference for initiating high-efficacy DMT at the time of initial MS diagnosis, opinions regarding the most appropriate treatment paradigm remain divided.
- 16 November 2024
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 25 (1) , 1-18
The Development of Epilepsy Following CNS Viral Infections: Mechanisms
Purpose of Review This review examines the role of different viral infections in epileptogenesis, with a focus on Herpesviruses such as Human Herpesvirus 6 (HHV-6) and Epstein Barr Virus (EBV), Flaviviruses, Picornaviruses, Human Immunodeficiency Virus (HIV), Influenzavirus and Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2). Recent Findings A growing literature on animal models, such as the paradigmatic Theiler’s murine encephalomyelitis virus (TMEV) model, and clinical investigations in patients with epilepsy have started to elucidate cellular mechanisms implicated in seizure initiation and development of epilepsy following viral infections. A central role of neuroinflammation has emerged, with evidence of activation of the innate and adaptive immunity, dysregulation of microglial and astrocytic activity and production of multiple cytokines and other inflammatory mediators. Several chronic downstream effects result in increased blood–brain barrier permeability, direct neuronal damage, and modifications of ion channels ultimately leading to altered neuronal excitability and seizure generation. Summary Key findings underscore the complex interplay between initial viral infection, neuroinflammation, and later development of epilepsy. Further research is needed to elucidate these mechanisms and develop targeted interventions.
- 16 November 2024
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 25 (1) , 1-18
The Development of Epilepsy Following CNS Viral Infections: Mechanisms
Purpose of Review This review examines the role of different viral infections in epileptogenesis, with a focus on Herpesviruses such as Human Herpesvirus 6 (HHV-6) and Epstein Barr Virus (EBV), Flaviviruses, Picornaviruses, Human Immunodeficiency Virus (HIV), Influenzavirus and Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2). Recent Findings A growing literature on animal models, such as the paradigmatic Theiler’s murine encephalomyelitis virus (TMEV) model, and clinical investigations in patients with epilepsy have started to elucidate cellular mechanisms implicated in seizure initiation and development of epilepsy following viral infections. A central role of neuroinflammation has emerged, with evidence of activation of the innate and adaptive immunity, dysregulation of microglial and astrocytic activity and production of multiple cytokines and other inflammatory mediators. Several chronic downstream effects result in increased blood–brain barrier permeability, direct neuronal damage, and modifications of ion channels ultimately leading to altered neuronal excitability and seizure generation. Summary Key findings underscore the complex interplay between initial viral infection, neuroinflammation, and later development of epilepsy. Further research is needed to elucidate these mechanisms and develop targeted interventions.
- Open Access
- 25 April 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (17) , 2400199
Severe A(H1N1)pdm09 influenza acute encephalopathy outbreak in children in Tuscany, Italy, December 2023 to January 2024
A severe outbreak of influenza A(H1N1pdm09) infection in seven children (median age: 52 months) occurred between December 2023 and January 2024 in Tuscany, Italy. Clinical presentation ranged from milder encephalopathy to acute necrotizing encephalopathy (ANE) with coma and multiorgan failure; one child died. This report raises awareness for clinicians to identify and treat early acute encephalopathy caused by H1N1 influenza and serves as a reminder of severe presentations of influenza in young children and the importance of vaccination.
- 25 April 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (17) , 2400199
Open AccessSevere A(H1N1)pdm09 influenza acute encephalopathy outbreak in children in Tuscany, Italy, December 2023 to January 2024
A severe outbreak of influenza A(H1N1pdm09) infection in seven children (median age: 52 months) occurred between December 2023 and January 2024 in Tuscany, Italy. Clinical presentation ranged from milder encephalopathy to acute necrotizing encephalopathy (ANE) with coma and multiorgan failure; one child died. This report raises awareness for clinicians to identify and treat early acute encephalopathy caused by H1N1 influenza and serves as a reminder of severe presentations of influenza in young children and the importance of vaccination.